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Abstract The prognostic outcome for hepatocellular carci-
noma (HCC) remains poor. Disease progression is accompa-
nied by dedifferentiation of the carcinoma, a process that is not
well understood. The aim of this study was to get more insight
into the molecular characteristics of dedifferentiated carcino-
mas using high throughput techniques. Microarray-based
global gene expression analysis was performed on five poorly
differentiated HCC cell lines compared with non-neoplastic
hepatic controls and a set of three cholangiolar carcinoma
(CC) cell lines. The gene with the highest upregulation was
HLXB9. HLXB9 is a gene of the homeobox genfamily
important for the development of the pancreas. RT-PCR
confirmed the upregulation of HLXB9 in surgical specimens
of carcinoma tissue, suggesting its biological significance.
Interestingly, HLXB9 upregulation was primary observed in
poorly differentiated HCC with a pseudoglandular pattern
compared with a solid pattern HCC or in moderate or well-
differentiated HCC. Additional the expression of translated
HLXB9, the protein HB9 (NCBI: NP_001158727), was
analyzed by western blotting. Expression of HB9 was only
detected in the cytoplasm but not in the nuclei of the HCC
cells. For validation CC were also investigated. Again, we
found an upregulation of HLXB9 in CC cells accompanied by
an expression of HB9 in the cytoplasms of these tumor cells,
respectively. In conclusion, homeobox HLXB9 is upregulated
in poorly differentiated HCC with a pseudoglandular pattern.
The translated HB9 protein is found in the cytoplasm of these
HCC and CC. We therefore assume HLXB9 as a possible link
in the understanding of the development of HCC and CC,
respectively.
Keywords Hepatocellular carcinoma . Cholangiocellular
carcinoma . HLXB9 . Histological differentiation
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignant tumor, with more than one million patients affected
worldwide each year and a generally very poor prognosis [1,
2]. Large-scale gene expression profiling has provided
important insights into the biology of HCC in recent years,
and there have been advances in terms of HCC etiology,
survival prediction, and the identification of signaling path-
ways that could serve as therapeutic targets [3–7]. Mutations
in several genes (e.g., P53, IGF2R, P16, PTEN) have been
associated with the development of HCC [8].
Morphological diagnosis of HCC is guided by criteria
defined in early studies still accepted as the standard for
pathologists [9, 10]. Over time, HCC tends to dedifferentiate
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morphologically. In more than half of all patients, dediffer-
entiation occurs within 7–34 months of diagnosis [11, 12].
Dedifferentiation is accompanied by increasing chromosomal
instability [13]. Dedifferentiation is also accompanied by the
occurrence of chromosomal imbalances, such as loss of 13q,
associated with loss of genes involved in cell cycle regulation
and proliferation [14]. Even more dedifferentiated HCC are
often difficult to separate from its cholangiocellular counter-
part, i.e., cholangiocarcinoma (CC).
Because morphological dedifferentiation of HCC is
associated with decreased survival time [15, 16], it is
important to elucidate the processes that lead to dediffer-
entiation. Towards this end, we analyzed poorly differen-
tiated cell lines derived from HCC and CC, respectively, to
search for candidate genes involved in dedifferentiation.
Surgical specimens were included to determine whether
these in vitro findings had biological relevance. Microarray-
based global mRNA expression analysis was performed at
first. Additional gene expression analysis, transfection- and
RNA-silencing assays were done to verify the results.
Using this approach, we identified the homeobox gene
HLXB9 as a gene that is likely to be involved in
morphological dedifferentiation in a subset of HCC.
Methods
Cell lines
The HCC cell lines HLE, HLF, Huh7, HepG2, and Hep3b
were kindly provided by Stefan Kubicka (Department of
Gastroenterology, Hannover Medical School, Germany). The
control cell lines were HHep (Provitro, Berlin, Germany), and
an immortalized hepatocytic cell line (HImo, kindly provided
by Prof. Dr. Didier Trono, Ecole Polytechnique Federale de
Lausanne, Switzerland). Since cryopreservation can influence
gene expression status [17], experiments were performed
both in freshly harvested cells and in cells that had been
cryopreserved. Additionally, three CC cell lines were
analyzed (EGI-1, MzCha1, TFK-1) kindly provided by
Nisar Malek (Department of Gastroenterology, Hannover
Medical School, Germany).
The hepatocellular origin of all HCC cell lines was
confirmed by immunohistochemistry (IHC) using antibodies
specific for CK8 and CK18, which are typically expressed in
hepatocytic cells. CK7 and CK19 were used to exclude
cholangiocellular differentiation. Ki67 was used for determi-
nation of proliferative activity (all antibodies supplied by
DAKO, Hamburg, Germany). IHC was performed on
histological sections of cells after formalin fixation and
paraffin embedding using the cell block technique (BBCBio-
chemicals, Seattle, WA, USA). All HCC cell lines with the
exception of Hep3b were positive for CK8 and CK18 and
negative for CK7 and CK19. Hep3b showed a positive
staining for CK19. The proliferation marker Ki67 was
positive in 54–88% of the nuclei of cells in all HCC cell
lines. Overall, proliferative activity and pleomorphism of
nuclei indicated a low differentiation (data not shown).
This was comparable for the CC cell lines. Here,
antibodies for CK7 and CK 19 were giving a positive
staining indicating cholangiocellular differentiation. Of the
nuclei, 45–55% were positive for Ki67 also indicating a
high proliferative activity.
Cell culture
Cell line HImo was maintained in DMEM plus 10% fetal
calf serum supplemented with glutamine and penicillin/
streptomycin at 37°C in a 5% CO2 atmosphere using
25 cm2 tissue culture flasks (TPP 90025, Oxoid, Prattelen,
Switzerland). Cell line HHep was cultured in hepatocyte
maintenance medium (Provitro, Berlin, Germany). Control
cell lines were maintained as recommended by the supplier.
Tumor cell lines were incubated in DMEM with 10% fetal
calf serum supplemented with glutamine and penicillin/
streptomycin at 37°C in a 5% CO2 atmosphere.
Mycoplasma infections were excluded using the Lookout
Mycoplasma PCR Detection Kit (Sigma, Germany). Growth
dynamics were determined by counting cells over a period of
at least 7 days. Cells were harvested in the ascending part of
the growth curve.
Surgical specimens
Twenty eight tumor tissues were obtained from 27 patients
as surgical specimens taken for diagnostic purposes
(permitted by the Ethics Committee of the University of
Bern). Tissues were paraffin-embedded after 24-h fixation
in 4% formaldehyde. Histological grading of tumors was
performed according to the WHO criteria [18].
For comparison of results obtained in these specimens, we
included also 10 samples of CC and five samples of
hepatocellular adenoma (HCA). As a control five non-
neoplastic tissues samples were chosen of livers ruptured
due to trauma.
mRNA isolation
For mRNA expression analyses of the cell lines, total RNA
was isolated using a commercially available system (Ambion,
Cambridge, UK). Transcription to cDNA was performed
using the High Capacity cDNA Reverse Transcription Kit
(#4374966, Applied Biosystems, Rotkreuz, Switzerland).
Five 10-μm sections were used for total RNA isolation from
formalin-fixed paraffin-embedded (FFPE) tissues. RNA was
isolated exactly as described previously [19]. One section was
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cut for H&E staining before sectioning material for mRNA
isolation, and one was cut just after sectioning. This ensured
the closest proximity and greatest homogeneity of tissues used
for experiments. The quality and quantity of total RNA was
determined photometrically (NanoDrop Technologies, Wil-
mington, Germany).
Microarray analysis
Awhole human genome oligonucleotide microarray kit was
used for global mRNA expression analysis (array G4112F,
Agilent, Waldbronn, Germany). This kit allows detection of
more than 41,000 unique human transcripts. After one-
color mRNA labeling and hybridization according to the
supplier’s instructions, microarray images were acquired
(Agilent Scanner System 2605, Waldbronn, Germany).
Hybridization spots were normalized using the feature
extraction software (version 9.5.3.1.) and processed as
described below.
mRNA microarray data from all four cell lines and the
control cell lines were further normalized and processed
using GeneSpring GX software version 9.0 (Agilent,
Waldbronn, Germany). GeneSpring software computes a
Table 1 Primers for qRT-PCR amplification using reagent concen-
trations and amplification conditions as specified by Applied
Biosystems
Gene symbol Assay ID Ref. Seq Amplicon
length (bp)
PXDN Hs00395488_m1 NM_012293.1 99
HLXB9 Hs00232128_m1 NM_005515.3 71
Gene symbol Accession no. Fold change Corrected p value
Upregulated genes
MNX1 NM_005515 364 0.00074790
LIN28B NM_001004317 43 0.00859069
TERT NM_198253 30 0.00976756
ELOVL7 NM_024930 18 0.00971980
PCDHB2 NM_018936 15 0.00051022
FAM184A NM_024581 11 0.00974849
PRKAA2 NM_006252 7 0.00051022
PCDHB11 NM_018931 6 0.00882593
ZCCHC2 BC006340 5 0.00406914
PCDHB13 NM_018933 5 0.00216112
SPRED2 NM_181784 4 0.00676678
DBNDD1 NM_001042610 4 0.00678942
MCM9 NM_153255 4 0.00582031
AGPAT9 NM_032717 4 0.00500372
DNMT3B NM_175850 4 0.004270845
Downregulated genes
PXDN NM_012293 2,199 0.00051022
COL1A1 Z74615 587 0.00971980
RAC2 NM_002872 559 0.00032802
GREM1 NM_013372 540 0.00009805
LZTS1 NM_021020 486 0.00026493
TOX2 NM_032883 376 0.00067963
CHST2 NM_004267 308 0.00223079
BNC1 NM_001717 266 0.00047324
RNF135 NM_032322 237 0.00047324
KRT7 NM_005556 202 0.00052403
PDLIM4 NM_003687 133 0.00018231
TMTC1 NM_175861 120 0.00089063
IL7R NM_002185 113 0.00042864
CDCP1 NM_022842 110 0.00348664
AR NM_000044 93 0.00029425
Table 2 Genes found to be
significantly (p<0.01) up-
(n=54) or downregulated
(n=125) in hepatocellular
carcinoma compared to non-
neoplastic cell lines using the
unpaired t test (asymptotic)
corrected for multiple testing
(Benjamini–Hochberg correction)
The 15 genes with the highest
fold changes for up- or
downregulation, respectively,
are listed here
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unique value for each miRNA and mRNA by taking the
average of replicates spotted on the microarrays. Specimens
were normalized using median normalization. HCC cell
lines were taken together as one group and non-neoplastic
hepatocytic cell lines as a second group. The mRNAs with
a positive or negative fold change >1.5 between these two
groups were further analyzed for significantly different
expression using an unpaired t test and the Benjamini–
Hochberg calculation for multiple test controls to reduce
false positive results. The level of significance was set at
p<0.01.
qRT-PCR
Quantitative reverse transcription-polymerase chain reac-
tion (qRT-PCR) using mRNA obtained from cell lines was
performed using the TaqMan® Universal PCR Master Mix
AmpErase® (#4324018, Applied Biosystems, Rotkreuz,
Switzerland) and the primers listed in Table 1. The cycling
conditions were set as instructed by the supplier. A real-
time PCR system (7500, Applied Biosystems, Rotkreuz,
Switzerland) was used for quantification.
mRNA from FFPE samples was measured using a
SuperScript™ III Platinum® One-Step qRT-PCR Kit follow-
ing the instructions of the supplier (#11732020, Invitrogen,
Basel, Switzerland). A 7500 Fast System (Applied Biosys-
tems, Rotkreuz, Switzerland) was used for quantification.
siRNA-based knock down of gene expression
HLXB9 was selectively suppressed by siRNA experiments
using a commercially available system (On-TARGETplus
SMARTpool system, Dharmacon, Chicago, IL, USA) with
a specific siRNA (Human HLXB9, DHARMACON). As a
negative control from the same supplier, we used the “On-
TARGETplus siCONTROL Non-targeting POOL”
reagents. mRNA of the manipulated cells was isolated as
described above.
Transfection experiments
Immortalized hepatocytic cell line was transfected with the
pCMV5-HLXB9 expression vector using the TurboFectin
8.0 reagent (Origene, Rockville, MD, USA). The media and
transfection components were used exactly as specified by
the supplier. The pCMV5 vector without the HLXB9 was
transfected as a negative control.
Separation of subcellular compartment proteins
The Qproteome cell compartment kit (Qiagen, Hilden,
Germany) was used to separate proteins in the following
cellular compartments: cytosol, membranes, and nucleus.
About 1×107 cells were harvested and lysed in accordance
with the Qiagen protocol. All buffers were supplemented
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Fig. 1 Graphical illustration
of intensity values obtained for
HLXB9 by microarray-based
expression analysis in HCC and
CC cell lines. Comparison was
done to non-neoplastic cell
lines. Dysregulation of HLXB9
is similar in both, HCC and CC
cell lines
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Fig. 2 qRT-PCR confirmed the results of microarray-based expression
analysis. RT-PCR analysis was conducted on the two genes with the
highest fold changes in hepatocellular carcinoma (HCC) cell lines:
PXDN, which was downregulated, and HLXB9, which was upregulated
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with protease inhibitors (as per the protocol) and 1 mM
NaVO3 as a phosphatase inhibitor. The resulting proteins
from each subcellular compartment were concentrated and
desalted by acetone precipitation. The pellets were then
resuspended in the appropriate buffer, which depended on
the analysis. Protein concentration was measured photomet-
rically (Biophotometer, Eppendorf, Hamburg, Germany).
Protein concentration in each sample was measured directly
by Bradford assay before SDS-PAGE (sodium dodecyl
sulfate polyacrylamide gel electrophoresis).
Immunoblot analysis
Proteins were separated by SDS-PAGE on 10% gels. A
prestained PageRuler protein ladder (#SM0671, Fermentas,
Germany) was included on each gel to standardize the
molecular weights of proteins in the samples. Following
protein transfer to nitrocellulose membranes (Amersham
Bioscience GmbH, Freiburg, Germany), the blots were
incubated with a monoclonal antibody against HB9
(ab79541, ABCAM, Germany). To verify that proteins in
subcellular compartments had been separated efficiently,
antibodies against marker proteins for the compartments were
used: anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for the cytosolic compartment and anti-actin
(#69100, MP Biomedicals, Ohio) for the nuclear compart-
ment. HLXB9 (48 kDa) and actin (42 kDa) are similar in size;
therefore the actin antibody was incubated subsequent to the
HB9 antibody. Following incubation with a peroxidase-
conjugated secondary antibody (Amersham, Germany), the
blots were developed using an electrochemiluminescence
detection kit (Perkin Elmer, Boston, MA, USA). Blot results
were scanned using a standard scanning device HP5470c
(Boeblingen, Germany). The digitized intensities were subse-
Gene symbol Accession no. Fold change Corrected p value
Upregulated genes
KLK10 NM_002776 2,944 0.00087690
TACSTD2 NM_002353 2,527 0.00455577
SPINT2 NM_021102 2,219 0.00058975
MALL NM_005434 1,913 0.00648792
GPR110 NM_153840 820 0.00485874
RAB25 NM_020387 688 0.00030306
ALDH1A3 NM_000693 653 0.00166345
RAC2 NM_002872 630 0.00224070
C19orf33 NM_033520 468 0.00284474
CDCP1 NM_022842 415 0.00305156
RNF135 NM_032322 415 0.00052486
BACE2 NM_012105 382 0.00168082
KLK10 NM_002776 360 0.00287167
GJB3 NM_024009 347 0.00061644
FXYD3 NM_005971 343 0.00966693
Downregulated genes
SDC2 NM_002998 1,620 0.00127171
GPC6 NM_005708 1,056 0.00281812
ACSS3 NM_024560 596 0.00348787
CDH2 NM_001792 399 0.00394804
LIN28B NM_001004317 387 0.00058975
EFHA2 NM_181723 376 0.00101820
MPDZ NM_003829 229 0.00052486
NID1 NM_002508 205 0.00168082
CBS NM_000071 180 0.00505487
ZIK1 NM_001010879 175 0.00140458
CBS NM_000071 131 0.00291453
DCDC2 NM_016356 127 0.00459634
LIN28B NM_001004317 118 0.00147870
ELOVL2 NM_017770 109 0.00532469
MYEF2 NM_016132 91 0.00201893
Table 3 Genes found to
be significantly (p<0.01) up-
(n=986) or downregulated
(n=191) in hepatocellular
carcinoma compared to
cholangiocarcinoma cell
lines using the parameter
as described above
The 15 genes with the highest
fold changes for up- or down-
regulation, respectively, are
again listed here
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quently analyzed and quantified using the ImageJ 1.36b
software (http://rsb.info.nih.gov/ij).
Results
Microarray-based mRNA analysis
Global mRNA expression analysis results were compared at
first in HCC tumor cell lines and non-neoplastic hepato-
cytic cell lines (all raw data can be obtained as additional
files from the authors). After use of the unpaired t test
corrected for multiple testing (Benjamini–Hochberg) for all
genes with a fold change >2, we identified 54 genes that
were significantly up-and 125 genes that were significantly
downregulated (p<0.01) in tumor cell lines (Table 2). The
highest fold changes were seen for MNX1 (also known as
HLXB9) mRNA, which was upregulated 364-fold, and for
PXDN mRNA, which was downregulated 2,199-fold
(Fig. 1). qRT-PCR was used to confirm these results
(Fig. 2).
We then looked for differential expression of HCC cell
lines compared to CC cell lines. Using the same criteria as
described above, 986 genes were up- and 191 genes were
downregulated, respectively (Table 3).
Comparing CC cell lines with non-neoplastic cell lines
led to the detection of 623 upregulated genes and 388
downregulated genes (Table 4). Again MNX1 (HLXB9)
was found upregulated with a high fold change of 572. In
contrast PXDN was not dysregulated significantly.
HLXB9 expression in cell lines
Since HLXB9 is a known homeobox gene involved in the
development of the pancreas and, most likely, cholangiocytes
[20], and was found upregulated in both HCC cell lines and
CC cell lines, further analysis was focused onto this gene.
For confirmation of the microarray based results, we
selectively knocked down expression of HLXB9 in HCC
cell lines by RNA interference using a known specific RNA
primer. This led to the most significant decrease of HLXB9
when using a concentration of 200 mM for 24 h of
incubation. HLXB9 was downregulated then to 12–29% in
HCC cell lines and to 18–43% in CC cell lines, respectively
(Fig. 3). We next transfected the immortalized hepatocytic
cell line with a pCMV5-HLXB9 vector. Microarray-based
mRNA analysis detected a 2,383-fold increase in HLXB9
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Fig. 3 siRNA-based knock down of HLXB9 in hepatocellular
carcinoma (HCC) cell lines. Using specific siRNAs, HLXB9 was
knocked down by 12–29% compared to controls defined as 100%.
The greatest inhibition of HLXB9 was observed after 12 h with
200 mM siRNA. In CC cell lines, downregulation was in the range of
19–42%
Table 4 Comparing CC cell lines with non-neoplastic cell lines
revealed 623 genes upregulated and 388 genes downregulated
Gene Accession no. Fold change Corrected p value
Upregulated genes
KLK10 NM_002776 1,258 0.0050223
OVOL1 NM_004561 592 0.00310259
MNX1 NM_005515 572 0.001556501
RAB25 NM_020387 482 0.001031751
ANO1 NM_018043 402 0.005484599
EPN3 NM_017957 307 0.001031751
TMEM125 NM_144626 291 0.007592963
KLK10 NM_002776 225 0.008101207
GJB2 NM_004004 189 0.004909608
FUT3 NM_000149 176 0.008854575
TNS4 NM_032865 162 0.002774253
GRHL2 NM_024915 155 0.004259103
ATP2C2 NM_014861 148 0.005392212
LOC645249 BC033117 143 0.006074598
TMC5 NM_024780 138 0.005551621
Downregulated genes
EFEMP1 NM_004105 17,326 0.00017120
CNN1 NM_001299 2,612 0.00007205
GJA1 NM_000165 2,105 0.00015593
PDGFRB NM_002609 2,051 0.00290483
SPARC NM_003118 1,693 0.00442776
COL5A1 NM_000093 1,298 0.00523753
SDC2 NM_002998 1,247 0.00145708
GPC6 NM_005708 1,221 0.00885457
ODZ2 NM_001122679 1,180 0.00140017
LAYN NM_178834 1,146 0.00442776
GREM1 NM_013372 955 0.00097044
PNMAL1 NM_018215 944 0.00030502
SNURF NM_022804 916 0.00144029
ADAMTS1 NM_006988 904 0.00011429
SNRPN NM_022807 840 0.00030502
Within the group of 15 genes with the highest fold changes HLXB9 is
again found
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mRNA in the transfected cells. Immunoblot analysis for
HB9 revealed a clear band at 48 kDa; this band was not seen
in non-transfected cells (Fig. 4). Applying the pCMV5
vector only was giving negative results. We assumed
HLXB9 as identified correctly by these experiments.
Consistent with the results on mRNA expression level,
HCC and CC cell lines were also positive on the protein
level for HB9; HB9 was detected in the cytoplasmic and
cell membrane fractions, but not in the nuclear fraction
(Fig. 5). This was confirmed by immunohistochemical
analysis of HB9. HB9 staining was observed in the
cytoplasm but not in the nuclei (Fig. 6).
HLXB9 and HB9 in surgical HCC specimens
Based on our findings, we surmised that HLXB9 was stably
upregulated in HCC and CC cell lines. We next examined
HLXB9/HB9 expression in surgical HCC specimens that
had not been cultured by analyzing 29 surgical HCC
specimens from 28 patients as well as non-neoplastic liver
tissue from the same patients.
None of the 17 moderately or well-differentiated HCC
tissues expressed HLXB9 mRNA, nor did the corresponding
non-neoplastic tissues (Table 5). In contrast, 5/12 samples
with low histological differentiation (Edmondson grade III or
IV) [10] demonstrated HLXB9 mRNA upregulation. The
ΔΔct values were generally ∼22. An exception was case
B07-2284. Two samples were analyzed: one showed no
upregulation of HLXB9 mRNA; the other specimen showed
an upregulation compared to the non-neoplastic tissue.
Interestingly, the B07-2284 tumor without upregulation had
a solid growth pattern, whereas the tumor with upregulation
had a pseudoglandular pattern (Fig. 7).
We reevaluated all other poorly differentiated HCC and
found that poorly differentiated HCC that lacked HLXB9
upregulation grew in a solid pattern. Two of these HCC
48 kDa -
37 kDa -
HepG2
F0       F1     F2   F3       F0       F1       F2    F3    F0     F1      F2   F3     F0     F1 F2    F3 
F0 - total protein cell lysate
F1 - cytoplasm proteins
F2 - membrane proteins
F3 - nuclei protein
HB9
GAPDH
72 kDa -
55 kDa -
40 kDa -
35 kDa -
HB9 (48 kDa)
actin (43 kDa)
Huh7 HLF HLE
Fig. 5 HB9 immunoblot
analysis of four hepatocellular
carcinoma (HCC) cell lines after
separation of proteins in the sub-
cellular compartments (Tot total
cell lysate, Cyt cytoplasm, M
membranes, N nuclei). HB9 was
only detected in cytoplasmic and
membrane fractions but not in
the nuclei of carcinoma cells. As
an internal control GAPDH was
used. Since this gene is not
expressed in nuclei actin was
used as an additional control for
this compartment
%: immortalized hepatocytic cell line not transfected
* :immortalized hepatocytic cell line transfected with a pCMV5-
HLXB9 vector
control*control%
104
97
50
37
kDa
Fig. 4 Transfection of cell line HImo with the pCMV5-HLXB9
expression vector resulted in HB9 expression. The immunoblot shows
non-transfected and pCMV5-HLXB9-transfected cells
Fig. 6 Immunohistochemical detection of HB9 in Hep3b cells. HB9
was detected in the cytoplasm but not in the nuclei
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(B04-10840 and B05-24972) demonstrated remarkable
pleomorphic nuclei. In turn, poorly differentiated HCC
with upregulated HLXB9 mRNA demonstrated a pseudo
glandular pattern of growth. Indeed, two of these HCC
were difficult to differentiate from CC (B07-23968 and
B08-4419). Therefore, IHC for CK7 and CK19, respec-
tively, was done for these cases to exclude CC and probably
find progenitor cell derived subtype as described by Lee et
al. [21]. These stainings were giving variable results with
B08-4419 negative for CK7 and positive for CK19 and
B07-23968 positive for both markers as given in Table 6
and demonstrated in Fig. 8. Variable findings occurred also
for the other three HCC analyzed as listed in that Table.
In a very recently published paper of Wildenhain et al.
analyzing HLXB9-TEL positive acute myeloid leukemia in
children EDIL, ITGAV, KDR, SIGLEC6, CNTNAP%,
ANGPT1, DSG, and ITGA9, respectively, were detected
as upregulated. Since these genes are active in cell–cell
contact, we reevaluated our data for these genes. Indeed we
found EDIL, ITGAV, KDR, CNTNAP5, ANGPT1, ITGA
as upregulated in HCC and/or CCC, too. Detailed data are
given in Table 7.
HLXB9 in surgical CC, HCA, and non-neoplastic
specimens
Upregulation of mRNA encoding HLXB9 was found in 1/10
CC sample as listed in Table 8. In this sample, a clearly
glandular pattern of growth with moderately to low differen-
tiated tumor cells were seen. Two other CC with glandular
pattern were well or moderately differentiated. Six CC
revealed a solid growth pattern. No upregulation of HLXB9
was found in HCA and non-neoplastic liver samples.
Discussion
The morphological characteristics of HCC have been well-
established since Edmondson and Steiner published their
basic grading system in 1954 [9]. Most HCC demonstrate
moderate differentiation at the time of surgical intervention.
Well-differentiated HCC are rare, making up fewer than
10% of all HCC cases. In contrast, dedifferentiated HCC
are seen more frequently as the disease progresses [11, 12].
Since dedifferentiation is accompanied by decreased sur-
vival time [15, 16], we wished to gain insights into the
mechanisms underlying dedifferentiation.
Molecular analysis of HCC biopsies is hampered by the
accompanying non-neoplastic cells and by the variable
morphological differentiation of the carcinomas. To avoid
these issues, we began our investigation with HCC cell
lines. All of these HCC cell lines were highly proliferative,
which we assumed as an indicator of dedifferentiation
beside the pleomorphism of these cells.
Microarray-based mRNA expression analysis of these
cell lines identified a set of 54 upregulated and 125
downregulated genes in HCC. The HLXB9 gene was the
most upregulated and had the highest fold increase of any
gene. HLXB9 is an evolutionarily highly conserved
homeobox gene that belongs to the MNX gene class [22].
It is involved in differentiation of beta cells [20] and motor
neurons [23, 24]. During mouse embryonic development,
HLXB9 is expressed at somite day 8 in the notochord, the
dorsal gut endoderm, and the ventral endoderm at the
prospective pancreatic anlage [25]. Despite PDX1 muta-
tions that prevent pancreas development, the initial stadium
of the pancreas anlage is still developing when HLXB9 is
functionally expressed. HLXB9 is detected in a dorsal–
ventral gradient during embrogenesis of mice [26]. This is
in concordance with the observation that mice lacking
HLXB9 are missing dorsal pancreas rudiments. HLXB9
Table 5 Expression of HLXB9 in HCC surgical specimens
Case HLXB9 ΔΔ-ct values Histological grade
B08-4628 n.u. 2
B07-24021 n.u. 2
B04-17547 n.u. 1
B06-28291 n.u. 2
B08-3896 n.u. 2
B06-24377 n.u. 2
B05-9393 n.u. 2
B04-24966 n.u. 2
B04-1095 n.u. 2
B04-1420 n.u. 2
B03-15870 n.u. 2
B03-15602 n.u. 2
B05-25757 n.u. 2
B03-12301 n.u. 2
B03-15870 n.u. 2
B03-10403 n.u. 2/3
B03-20246 n.u. 2
B06-26164 n.u. 3
B05-24806 n.u. 3
B04-10840 n.u. 3
B05-24972 n.u. 3
B03-22359 n.u. 3
B07-2284 I n.u. 3
B07-23968 23.0 3
B07-2284 II 22.3 3
B08-4419 23.7 3
B06-11514 24.9 3
B08-2087 23.9 3
n.u. Not upregulated. ΔΔct values >35 in both, tumor and non-
neoplastic tissues
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Table 6 Immunohistochemical stainings for CK7 and CK19 in HCC
samples found upregulated for HLXB9
Case Detectable staining for
CK7 CK19
B07-23968 Yes Yes
B07-2284 II No Patchy
B08-4419 No Yes
B06-11514 Patchy No
B08-2087 No No
Staining pattern was variable. Beside cases with positive staining in all
cells and cases without any positive cells there were tumor samples
with variable expression of cytokeratins as named “patchy” here and
demonstrated in Fig. 8
Fig. 8 Immunohistochemical staining of case 2294–07 for CK7.
Ductular reactions serve as an internal positive control. Tumor cells
are giving a variable “patchy” pattern
a b
c
Fig. 7 Morphology of poorly differentiated HCC (a–c). In a, a pseudoglandular pattern is found; in b, a solid pattern is shown; in c, solid pattern
with highly irregular nuclei of HCC is demonstrated. In cases of pseudoglandular pattern upregulation of HLXB9 was detectable
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mutations are rare and cause Currarino syndrome, an
autosomal dominant congenital malformation that causes
anorectal malformations and sacral agenesis [27].
In malignant transformed cells such as Hodgkin lym-
phoma cell lines, HLXB9 activates IL6 and is regulated by
PI3K signaling that involves E2F3 [28]. van Bergh et al.
reported a high incidence of t(7;12)(q36;p13) in infant
AML with a poor outcome and ectopic expression of
HLXB9. HLXB9 upregulation is mirrored by an intracel-
lular shift away from the periphery (cytoplasm) to a more
central position in the nucleus [29]. It is of high interest,
that activation of IL6 together with NF-κB and dysregula-
tion of miRNAs Lin28, and Let-7 can lead to an epigenetic
shift involved in the development of a neoplastic growth of
tumor cells [30]. Although we did not find direct evidence
of upregulation of IL6 in the cell lines analyzed here, we
assume this as an important point to consider for further
research purposes.
We confirmed upregulation of HLXB9 in surgical HCC
specimens in a subgroup of poorly differentiated HCC with a
pseudoglandular pattern of growth. Indeed, in two samples, it
was not easy to differentiate HCC from CC. We therefore
looked also for expression of CK7 and CK19, since these
intermediar filaments are expressed in CC and also in a subset
of HCC with impaired clinical outcome [21]. Interestingly,
those samples revealing upregulation of HLXB9 in our study
expressed at least one of these cytokeratins in a uniform or
patchy pattern. As demonstrated in the study mentioned
above, this subset of HCC reveals gene expression patterns
of hepatoblasts. Differentiation of hepatocytes and cholan-
giocytes is not finished at this time which is in concordance
with the assumption that tumors cells of this particular group
of HCC derive from a progenitor cell. Unfortunately in the
article mentioned above, photographs of immunostainings
are not given for direct comparison. Nevertheless, we
assume this as an important aspect worth spending further
efforts on. In contrast, to HCC with pseudo glandular
pattern, HCC revealing solid growth were not associated
with increased expression of HLXB9, nor were moderate- or
well-differentiated HCC. By these findings, we speculate
that poorly differentiated HCC with a pseudoglandular
Case Histological diagnosis Histological pattern Grade HLXB9 ΔΔ-ct values
B04-17723 CC Solid G3 n.u.
B05-11029 CC Glandular G1 n.u.
B05-32694 CC Solid/trabecular G2 n.u.
B06-1266 CC Solid/trabecular G2 n.u.
B06-6539 CC Solid/trabecular G2 n.u.
B06-11307 CC Glandular G2 n.u.
B06-14496 CC Solid/trabecular G2 n.u.
B07-4482 CC Solid/trabecular G2 n.u.
B07-5154 CC Glandular G2-3 11,7
B07-13723 CC Solid/trabecular G2 n.u.
B09-14730 HCA n.u.
B07-13618 HCA n.u.
B06-15259 HCA n.u.
B01-19096 HCA n.u.
B04-30498 HCA n.u.
B03-29375 Non-neoplastica n.u.
B05-12945 Non-neoplastic n.u.
B05-29110 Non-neoplastic n.u.
B09-19946 Non-neoplastic n.u.
B09-31593 Non-neoplastic n.u.
Table 8 Expression of HLXB9
in samples of CC, HCA, and
non-neoplastic liver specimens
n.u. Not upregulated. ΔΔct val-
ues >35 in both, tumor and non-
neoplastic tissues
a Obtained from livers ruptured
due to trauma
Table 7 Wildenhain et al. reported eight genes upregulated in
HLXB9/TEL translocated childhood AML
Gene Cell lines
HCC CCC
EDIL3 10 27
ITGAV 2.4 <2
KDR 4.5 5.3
CNTNAP5 <2 2.2
ANGPT1 <2 31
ITGA9 <2 2.7
These genes are acting in cell–cell contact. Six of these genes were
also found upregulated in HCC and/or CCC cell lines in our study
with the fold changes given below. EDIL3 war remarkable highly
expressed in CCC as discussed in the text
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pattern could reflect an mRNA expression pattern that is
related to a cholangiolar expression pattern. This would be in
concordance with the finding of upregulation of HLXB9 in
the CC cell lines examined here since growth of both
carcinoma types in one tumor has been reported repeatedly,
HLXB9 could be a link [10]. Further, hepatocytes and
cholangiocytes are assumed to be derived from hepatoblast/
oval cells, since the same progenitor cells localize to the
ductal plate area [31].
Interestingly, all HCC cell lines, but only half of the
surgical specimens of poorly differentiated HCC demon-
strated HLXB9 upregulation. This raises the question of
whether there is a bias in terms of the morphological
subtype of the HCC cell line. This may be related to the
observation that HCC tumor cells are difficult to establish
in vitro. It seems likely that a particular subtype of HCC
cell is needed for successful growth in vitro. Since the cell
lines analyzed here were grown as suspensions, we cannot
address this question at this time.
Very recently Wildenhain et al. [32] reported the
expression of cell–cell interacting genes upregulated in
childhood acute myeloid leukemia bearing a HLXB9-TEL
translocation and HB9 overexpression. They found an
upregulation of eight genes, six of them upregulated at
least twofold in HCC and/or CCC cell lines in our study,
too. EGF-like repeats and discoidin I-like domains 3
(EDIL3) was found upregulated highest in both tumor
types. This gene encodes the protein of an integrin ligand. It
is important in mediating angiogenesis and probably plays a
role in vessel wall remodeling and development (as
describe in RefSeq). Interestingly, EDIL3 is correlated to
a shorter survival of HCC patients as reported by Sun et al.
[33]. As HCC and CCC of low differentiation are correlated
to a shorter survival of patients and also express HLXB9 in
a number of such tumors as shown here, it may be
speculated that there could be a link. Unfortunately, Sun
et al. did not provide their data in regard to the grading of
the tumors analyzed.
In conclusion, HLXB9 is significantly upregulated in
HCC and CCC cell lines and in poorly differentiated HCC
with a pseudoglandular pattern. The protein encoded by
HLXB9, HB9, is found only in the membrane and
cytoplasm of these tumor cells. This observation may
provide insights into the mechanism(s) underlying devel-
opment of malignancy and dedifferentiation in hepatocel-
lular and cholangiolar cells.
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